JNJ

Rating neutralTentativeAI MemoPost-earnings T+3

Johnson Johnson

As of 2026-07-20/Post-earnings T+3/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-20 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Action

neutral

Confidence

high

Horizon

—

Key catalyst

Q2 results and raised 2026 outlook • 2026-07-15

Base target: $275 / p=55% prob

Biggest risk

The stock initially fell 2.69% on the release date before recovering over the next two sessions, suggesting the beat was not a clean re-rating catalyst. GAAP EPS declined 0.9% year over year, and the core debate remains whether new medicines and MedTech can sustainably offset STELARA pressure and execution risks.

Invalidation

Break below $225 or thesis failure.

What would change my mind?

The Q2 result strengthened the operating floor: sales grew 6.6%, adjusted EPS grew 4.7%, and management raised both sales and EPS guidance. Post-print analyst actions were broadly constructive, including Guggenheim Buy at $270, Bernstein's target increase to $261, and Freedom Capital's upgrade with a $280 target. [#SEC-8K-2026-07-15] [Guggenheim](https://www.investing.com/news/analyst-ratings/guggenheim-reiterates-johnson--johnson-stock-rating-on-q2-beat-93CH-4795505) [Bernstein](https://www.investing.com/news/analyst-ratings/bernstein-raises-johnson--johnson-stock-price-target-on-earnings-beat-93CH-4796054) [Freedom Capital](https://www.investing.com/news/analyst-ratings/freedom-capital-upgrades-johnson--johnson-stock-rating-on-strong-quarter-93CH-4796593)

Research note

Recommendation

neutral

Confidence

high

As of

2026-07-20

Base target

$275

p=55%

Bull target

$300

p=20%

Bear target

$225

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Mixed-positive post-print analyst revisions
Pipeline approvals and commercial replacement growth
The Q2 result strengthened the operating floor: sales grew 6.6%, adjusted EPS grew 4.7%, and management raised both sales and EPS guidance.

BearKey bullets

Analyst revisions were constructive but mixed, with Bernstein retaining Market Perform; broader estimate-revision coverage remains limited.
Pipeline, regulatory, launch, and commercial-uptake execution remain necessary to sustain the raised outlook.
[#SEC-8K-2026-07-15]

WatchKey bullets

Q2 results and raised 2026 outlook

Summary

High-level snapshot

Recommendation

neutral

Model confidence

high

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $275 (p=55%)

Target spread vs base: +9% / -18%

Scenario probabilities

Bull Target: $300 (p=20%)Base Target: $275 (p=55%)Bear Target: $225 (p=25%)

Commentary

Post-earnings tone is moderately positive but market confirmation is incomplete. JNJ beat adjusted EPS expectations, raised guidance, and received several constructive analyst updates, while shares fell 2.69% on July 15 before rising 1.19% and 1.23% on July 16-17. The mixed initial reaction and limited target-dispersion data support monitoring rather than an aggressive bullish stance. [Johnson & Johnson Q2 2026 results](https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-reports-Q2-2026-results-raises-2026-outlook/default.aspx) [JNJ historical prices](https://ca.investing.com/equities/johnson-johnson-historical-data)

As of 2026-07-20 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Mixed-positive post-print analyst revisions
Pipeline approvals and commercial replacement growth

Scenarios

Bull Target (Scenario probability)

$300 / p=20% prob

Base Target (Scenario probability)

$275 / p=55% prob

Bear Target (Scenario probability)

$225 / p=25% prob

Analysis 2026-07-20 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-07-15
Q2 results and raised 2026 outlook
JNJ reported Q2 sales of $25.31 billion, adjusted EPS of $2.90, and raised 2026 guidance to $101.1 billion reported sales and $11.68 adjusted EPS at the midpoint. Innovative Medicine operational growth was 6.8%, driven by DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE, TREMFYA, SPRAVATO, and CAPLYTA, while STELARA reduced growth by approximately 760 basis points. [#SEC-8K-2026-07-15] [SEC Exhibit 99.1](https://www.sec.gov/Archives/edgar/data/200406/000020040626000146/a2026q2exhibit991.htm)
Prob 85.00% • Move 3.50% • Priced-in 80.00%
EVENT2026-12-08
Enterprise Business Review provides a dated strategic checkpoint
Management scheduled an Enterprise Business Review for December 8, 2026, creating a dated opportunity to clarify the path toward double-digit growth and portfolio priorities. [#SEC-8K-2026-04-14]
Prob 65.00% • Move 4.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

Mixed-positive post-print analyst revisions
2026-07-16
Guggenheim maintained Buy and a $270 target after the Q2 report; Bernstein raised its target from $251 to $261 while retaining Market Perform, and Freedom Capital upgraded JNJ to Buy with a $280 target from $230. Guggenheim coverage cited adjusted EPS of $2.90 versus a $2.85 consensus estimate. [Guggenheim](https://www.investing.com/news/analyst-ratings/guggenheim-reiterates-johnson--johnson-stock-rating-on-q2-beat-93CH-4795505) [Bernstein](https://www.investing.com/news/analyst-ratings/bernstein-raises-johnson--johnson-stock-price-target-on-earnings-beat-93CH-4796054) [Freedom Capital](https://www.investing.com/news/analyst-ratings/freedom-capital-upgrades-johnson--johnson-stock-rating-on-strong-quarter-93CH-4796593)
Prob 70% • Move 2% • Priced-in 78%

Long-term Catalysts

Months to a year

Pipeline approvals and commercial replacement growth
2027-07-20
The company highlighted approvals for TREMFYA and CAPLYTA and future data from RYBREVANT FASPRO, TALVEY plus DARZALEX FASPRO, and OTTAVA. Longer-term upside depends on these assets and MedTech growth offsetting continued STELARA pressure. [#SEC-8K-2026-07-15]
Prob 58% • Move 7% • Priced-in 55%

Risks

Analyst revisions were constructive but mixed, with Bernstein retaining Market Perform; broader estimate-revision coverage remains limited.
Pipeline, regulatory, launch, and commercial-uptake execution remain necessary to sustain the raised outlook. [#SEC-8K-2026-07-15]
Reported net earnings were essentially flat year over year and GAAP EPS declined despite adjusted EPS growth.
STELARA reduced Innovative Medicine operational growth by approximately 760 basis points in Q2, leaving replacement growth as a central execution requirement. [#SEC-8K-2026-07-15]
The initial post-earnings price reaction was negative, and the available target upside is moderate rather than transformational.

Peers

Symbol	Summary
ABBV	Direct branded-pharma comparator with immunology, oncology, and neuroscience exposure; useful for testing whether JNJ can replace legacy-product erosion with newer-franchise growth.
MRK	Large-cap pharma comparator with concentrated oncology exposure; relevant for comparing JNJ's diversification against a more focused innovation profile.
AZN	Global biopharma comparator with oncology and specialty-medicine growth; useful for benchmarking JNJ's pipeline and commercial execution.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-20

Loading AI feed…

Symbol

Summary

ABBV

Direct branded-pharma comparator with immunology, oncology, and neuroscience exposure; useful for testing whether JNJ can replace legacy-product erosion with newer-franchise growth.

MRK

Large-cap pharma comparator with concentrated oncology exposure; relevant for comparing JNJ's diversification against a more focused innovation profile.

AZN

Global biopharma comparator with oncology and specialty-medicine growth; useful for benchmarking JNJ's pipeline and commercial execution.